Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AGL · against 456 other Healthcare companies of similar size
Ranked #328 of 457 · scores higher than 8% of peers
Bars: peers in each 10-point band of the valuation score130 peers with a valuation score of 0–9, including AGL · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | AGL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 445 reported | -17.6% | 1.5% | 8% | 30% | |
| EBITDA yieldHigher is better · 460 reported | -18.1% | 4.5% | 7% | 50% | |
| Free cash flow yieldHigher is better · 209 reported | -7.2% | -0.5% | 27% | 20% | |
| Book yieldHigher is better · 449 reported | 15.4% | 39.2% | 18% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 328 | 7.5B CNY (≈$1.1B) | 8 | 26 | |
| 328 | 1.3B USD | 8 | 15 | |
| 328 | 1.7B USD | 8 | 23 | |
| 328 | 1.9B USD | 8 | 49 | |
| 328 | 1.5B USD | 8 | 26 | |
| 328 | 831M USD | 8 | ||
| 328 | 841M USD | 8 | 33 | |
| 328 | 794M USD | 8 | ||
| 328 | 891M USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score